Secondary analysis of MARIPOSA in EGFR-mutated advanced NSCLC: first-line amivantamab-lazertinib vs osimertinib had fewer acquired MET amplifications (3.4% vs 13.1%) and secondary EGFR mutations (1.4% vs 7.6%), and longer median second-line PFS (8.4 vs 5.3 mo; nominal p=0.02).
Secondary analysis
Hayashi et al. Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report